Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...
After hours: January 14 at 5:13:24 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback